Below you'll find information about our ongoing studies. Please let us know if you are interested in participating. The contact information for each study is listed along with the study descriptions below. If you would like to participate in a study, but do not know which you qualify for, please call our study staff at (415) 221-4810 ext 24117, or email [email protected]. Click here to learn about our Completed Studies.
PhROST (Pharmaco-Imaging Responses to Oxytocin in Schizophrenia)
A pharmaco-imaging approach to predicting social functioning and clinical responses to oxytocin administration in schizophrenia
This study aims to test whether oxytocin could be an effective treatment for social functioning deficits in schizophrenia. We will examine changes in brain activation to understand how oxytocin affects behavior and to predict which individuals may benefit from oxytocin treatment.
If you would like to participate as a patient, please call (415) 221-4810 ext 24117 or email [email protected] for more information.
PINC (Psilocybin for Immunity, Neuroplasticity, and Cognition)
Effects of psilocybin on cognition, neuroplasticity, and immune function in adults with major depressive disorder (MDD)
This ancillary project will allow participants enrolled in the Usona Institute parent study at our site to optionally engage in additional assessments and behavioral testing to gather data on changes to learning, cognition, emotion, and immune function before and after their study drug session.
FEQ (Facilitator Experience Questionnaire)
A quantitative survey study assessing the psychedelic training and experiences of psilocybin study therapists
We are interested in identifying the optimal training necessary to prepare mental health personnel to provide psilocybin therapy in our clinical trails. The purpose of FEQ is to conduct the first quantitative study of psilocybin therapists' backgrounds and perspectives regarding psychedelic medicine experiences and treatment. By inviting survey input from clinicians providing therapy in Usona Institute's Phase 2 study of psilocybin for major depressive disorder (MDD), this project will help us conceptualize and plan personnel recruitment and training in our future psilocybin studies.
Usona Institute Psilocybin for MDD Study
A Randomized, Double-Blind, Support-of-Concept Phase 2 Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)
UCSF is one of seven research sites engaged with the study sponsor, USONA, to conduct this study and to potentially continue into Phase 3 testing.
MDMA for PTSD Study
A Study of the Safety and Effect of Manualized MDMA-Assisted Psychotherapy for the Treatment of Severe Posttraumatic Stress Disorder
This Phase 3 study is centered around understanding the underlying mechanisms through which MDMA coupled with psychotherapy may be useful for the treatment of PTSD.